XML 70 R51.htm IDEA: XBRL DOCUMENT v3.22.4
Acquisitions and divestitures - Teneobio Inc. (Details)
$ in Millions
12 Months Ended
Dec. 31, 2022
USD ($)
Dec. 31, 2022
USD ($)
program
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Business Acquisition [Line Items]        
Additions   $ 0 $ 309 $ 0
Goodwill $ 15,529 15,529 $ 14,890 $ 14,689
Teneobio        
Business Acquisition [Line Items]        
Goodwill, Purchase Accounting Adjustments   22    
Cash purchase price 993      
Maximum additional consideration due contingent on certain milestones 1,600 1,600    
Additions 299      
Deferred tax liabilities 244 244    
Goodwill 273 273    
Teneobio | R & D Technology rights        
Business Acquisition [Line Items]        
Finite-lived Intangible Assets Acquired $ 115      
Weighted average period of amortization 10 years      
Teneobio | Licensing rights        
Business Acquisition [Line Items]        
Finite-lived Intangible Assets Acquired $ 41      
Teneobio | IPR&D        
Business Acquisition [Line Items]        
Acquired in-process research and development 991 $ 991    
Number of oncology programs comprising remaining IPR&D | program   4    
Teneobio | IPR&D | AMG 340        
Business Acquisition [Line Items]        
Acquired in-process research and development $ 784 $ 784